- Report
- December 2025
- 283 Pages
Global
From €5180EUR$5,850USD£4,530GBP
- Report
- August 2025
- 142 Pages
Global
From €2257EUR$2,549USD£1,974GBP
€2655EUR$2,999USD£2,322GBP
- Report
- October 2025
- 196 Pages
Global
From €3139EUR$3,545USD£2,745GBP
€3488EUR$3,939USD£3,050GBP
- Report
- January 2025
- 183 Pages
Global
From €3985EUR$4,500USD£3,484GBP
- Report
- October 2025
- 192 Pages
Global
From €3139EUR$3,545USD£2,745GBP
€3488EUR$3,939USD£3,050GBP
- Report
- August 2025
- 194 Pages
Global
From €3139EUR$3,545USD£2,745GBP
€3488EUR$3,939USD£3,050GBP
- Report
- March 2025
- 180 Pages
Global
From €3985EUR$4,500USD£3,484GBP
- Report
- December 2025
- 213 Pages
Global
From €5180EUR$5,850USD£4,530GBP
- Report
- December 2025
- 158 Pages
Global
From €5180EUR$5,850USD£4,530GBP
- Report
- April 2025
- 250 Pages
Global
From €3976EUR$4,490USD£3,477GBP
- Report
- February 2025
- 200 Pages
Global
From €3976EUR$4,490USD£3,477GBP
- Report
- February 2025
- 200 Pages
Global
From €3976EUR$4,490USD£3,477GBP
- Report
- June 2025
- 400 Pages
Global
From €4382EUR$4,949USD£3,832GBP
- Report
- January 2025
- 210 Pages
Global
From €4423EUR$4,995USD£3,868GBP
- Report
- August 2025
- 150 Pages
Global
From €2524EUR$2,850USD£2,207GBP
€3409EUR$3,850USD£2,981GBP
- Report
- August 2023
- 1500 Pages
Global
From €7748EUR$8,750USD£6,775GBP
- Report
- June 2022
- 55 Pages
India
From €4427EUR$5,000USD£3,872GBP
- Report
- June 2021
- 197 Pages
Latin America
From €3542EUR$4,000USD£3,097GBP
- Report
- February 2024
- 72 Pages
South Korea
From €4427EUR$5,000USD£3,872GBP
- Report
- January 2023
- 195 Pages
Latin America
From €4427EUR$5,000USD£3,872GBP

The NAT Screening market within the context of In Vitro Diagnostics is a segment of the healthcare industry that focuses on the development and commercialization of tests that detect the presence of infectious agents in a sample. These tests are used to diagnose and monitor the spread of infectious diseases, such as HIV, hepatitis, and other viruses. NAT Screening tests are used in a variety of settings, including clinical laboratories, hospitals, and public health departments.
NAT Screening tests are typically performed using a variety of technologies, such as polymerase chain reaction (PCR), nucleic acid hybridization, and enzyme-linked immunosorbent assays (ELISA). These tests are used to detect the presence of specific genetic material in a sample, which can be used to identify the presence of a particular infectious agent.
Some companies in the NAT Screening market include Abbott Laboratories, Becton Dickinson, Cepheid, Hologic, and Roche Diagnostics. Show Less Read more